Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005624 · ClinicalTrials.gov registry record · Phase 2
CI-994 in Treating Patients With Advanced Myeloma
A Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00005624: Completed Phase 2 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT00005624 is a Phase 2 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005624, a Phase 2 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have advanced myeloma.
Primary Outcome
Response Rate according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria.
Interventions
- DRUG CI-994
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 1997-08 |
| Est. Completion | 2003-02 |
| Phase | Phase 2 |
What the finished NCT00005624 record still lists
NCT00005624 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which CI-994 is the first listed.
NCT00005624 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005624 about?
NCT00005624 is a clinical study titled "CI-994 in Treating Patients With Advanced Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CI-994 in treating patients who have advanced myeloma.
What is the current status of trial NCT00005624?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 1997-08. Estimated completion is 2003-02.
What interventions are being tested in trial NCT00005624?
The interventions under investigation include: CI-994 (DRUG).
Who is sponsoring clinical trial NCT00005624?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005624's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia